Tag - novartis

 
 

NOVARTIS

An employee looks at data on screens in the high-tech command center at the Novartis AG campus in Basel, Switzerland.
BUSINESS / Companies
Jan 10, 2024
Swiss pharma firms plot different paths to blockbuster drugs
Roche has doubled down on Alzheimer’s and boosted research and development spending across its portfolio.
Japan Times
WORLD / Science & Health
Jun 3, 2023
Breast cancer drug shown to reduce recurrence risk
Even when the disease is caught early, breast cancer recurrence is relatively common — and for survivors, the prospect can be daunting.
Japan Times
JAPAN / Science & Health
May 13, 2020
Japan's health insurance to cover ¥167 million gene therapy drug
Considered the world's most expensive medicine, relatively few cases are expected to require the one-time dosage of drug to treat spinal muscular atrophy.
Japan Times
JAPAN / Science & Health
Feb 26, 2020
Japanese government panel OKs expensive gene therapy for rare disease
A health ministry panel approved the production and sales of a gene therapy for treating spinal muscular atrophy, a rare incurable disease that destroys muscle function.
Japan Times
BUSINESS / Companies
Nov 25, 2019
Novartis agrees to buy Medicines Co. in $6.8 billion deal targeting promising cholesterol drug
Novartis AG agreed to buy Medicines Co. for an equity value of about $6.8 billion, snapping up a promising cholesterol drug and adding to a string of acquisitions for Chief Executive Officer Vas Narasimhan.
Japan Times
BUSINESS
Aug 8, 2019
Novartis says it knew of Zolgensma data problems before U.S. approval
Swiss Drugmaker Novartis AG on Wednesday said it knew about discrepancies in data it submitted to regulators as it sought approval of its more than $2 million gene therapy Zolgensma, but delayed notifying authorities until it completed an internal investigation.
Japan Times
JAPAN / Science & Health
May 15, 2019
Health insurance in Japan to cover new cancer therapy that costs ¥33 million
The anti-cancer drug Kymriah will be produced by a Tokyo-based unit of Novartis AG and is expected to carry the highest price tag of any single drug in Japan.
Japan Times
BUSINESS / Companies
May 9, 2019
Takeda sells dry-eye drug to Novartis for deal valued at up to $5.3 billion
Takeda Pharmaceutical Co. Ltd has agreed to sell its dry eye drug to Swiss drugmaker Novartis AG for $3.4 billion and potential milestone payments of up to $1.9 billion, in the first divestment since its takeover of the U.K.'s Shire.
BUSINESS
May 10, 2018
Novartis ends contract with firm linked to Trump lawyer Michael Cohen, calling ties a mistake
Swiss drugmaker Novartis has ended a contract with a firm linked to U.S. President Donald Trump's lawyer, Michael Cohen, saying it was now seen as a mistake.
Japan Times
JAPAN / Science & Health / A MATTER OF HEALTH
Nov 15, 2017
Japanese doctor who exposed a drug too good to be true calls for morality and reforms
It was a gut feeling and common sense that made Dr. Iwao Kuwajima question a drug for high blood pressure that just about every other doctor in his field was excited about in the 2000s.
BUSINESS
Sep 11, 2017
Novartis posts win, Roche a flop in drug trials targeting skin cancer
Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group.
BUSINESS / Companies
Nov 11, 2015
Novartis Japan faces censure for delay in disclosing drug side effects
The health ministry will censure a Japanese unit of Swiss pharmaceutical giant Novartis AG for failing to report serious side effects from some of its drugs within a certain period of time, sources close to the matter said Wednesday.
WORLD / Science & Health
Jul 9, 2015
Progress reported in using gene therapy for deafness
Gene therapy for deafness is moving closer to reality, with new research on Wednesday showing the technique for fixing faulty DNA can improve responses in mice with genetic hearing loss.
BUSINESS
Feb 3, 2015
Novartis Japan unit faces business suspension order
The health ministry will order a business suspension of around 15 days for a Japanese unit of Swiss pharmaceutical maker Novartis AG for not reporting serious side effects of its drugs, sources close to the matter said on Monday.
EDITORIALS
Sep 4, 2014
Novartis drug probe falls short
The Tokyo criminal probe into the manipulation of clinical data pertaining to the efficacy of a Novartis Pharma-marketed drug for blood pressure has failed to unravel the whole picture of the scandal.
JAPAN / Crime & Legal
Jul 1, 2014
Novartis Pharma, ex-employee charged over drug data manipulation
Tokyo prosecutors charged Novartis Pharma K.K. and a former employee Tuesday with causing a medical research team to release data manipulated in favor of the firm's drug for treating high blood pressure in 2011.
JAPAN / Crime & Legal
Jun 11, 2014
Ex-Novartis worker seized for faking clinical trial data of blood pressure drug
A former employee of Novartis Pharma K.K. has been arrested for allegedly manipulating clinical study data for one of the companyu2019s drugs.
Japan Times
JAPAN
Feb 27, 2014
Diovan scandal traced to cozy doctor-drugmaker ties
The manipulation of clinical research data used to develop the blood pressure drug Diovan sold by Novartis Pharma K.K. has prompted a special squad of Tokyo prosecutors to search the Japanese unit of the Swiss drugmaker as well as the universities that conducted the research.
JAPAN
Feb 19, 2014
Tokyo prosecutors raid Novartis Pharma over drug ads
Tokyo prosecutors raided Novartis Pharma K.K. on Wednesday over its alleged use of exaggerated advertising for a blood pressure-lowering drug, following a criminal complaint filed by the health ministry last month.
Japan Times
JAPAN / EXPLAINER
Jan 13, 2014
Novartis drug's data-tampering reflects unchecked collusion
Last week, the Health, Labor and Welfare Ministry filed a criminal complaint with prosecutors against Novartis Pharma K.K., the Japanese subsidiary of Swiss pharmaceutical giant Novartis, alleging the firm made exaggerated advertising claims for its blockbuster blood pressure drug Diovan.

Longform

Hideo Shimoju points to a possible site that his fellow neighbors may relocate to. Such relocations have happened before, but not preemptively.
In disaster-prone Japan, some communities consider major moves